Argonaute proteins are evolutionarily conserved effectors that mediate sequence-specific gene silencing through association with small RNAs. Upon biogenesis by the Dicer family of RNase III enzymes, ...
In adults with chronic hepatitis B infection receiving viral suppression therapy, coupling an investigational small interfering RNA therapy with an immunomodulator led to substantial declines in blood ...
Plant molecular evolution offers key insights into how coding and regulatory changes shape the diversity of form and function across the plant kingdom. The ...
Under the terms of the agreement, GSK will obtain exclusive worldwide rights to develop, manufacture, and commercialize two of Frontier Biotech's Small Interfering RNA (siRNA) pipeline products, one ...
Small interfering RNA (siRNA) drugs are a class of therapeutic agents that silence specific genes associated with inherited diseases. However, siRNA drugs have challenges because siRNAs often silence ...
Editor’s Note: Please see the article for additional information, including other authors, author contributions and affiliations, conflict of interest and financial disclosures, and funding and ...
Company advances its leadership in MASH with clinical-stage, genetically targeted siRNA asset from Arrowhead PharmaceuticalsPrecision approach ...
Pharmaceutical Technology on MSN
Madrigal outlays $1bn for Arrowhead’s siRNA MASH asset
As with its previous siRNA deal, Madrigal plans to explore whether gene-silencing could complement its lead drug Rezdiffra.
This deal strengthens GSK’s focus on addressing the complications of obesity, while restocking the company’s pipeline amid ...
The MarketWatch News Department was not involved in the creation of this content. NANJING, China, Feb. 24, 2026 /PRNewswire/ -- Frontier Biotechnologies Inc. (hereinafter referred to as "Frontier ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results